Sat, Aug 30, 2014, 12:56 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • boxcarlong boxcarlong Apr 11, 2013 1:19 PM Flag

    SYNERGY Trial interim analysis - Efficacy & Utility

    First of per management there is no interim analysis schedules for efficacy

    The definition for interim analysis for efficacy: To see if the new treatment is overwhemingly better than the control group. If Yes than stop trial pass go and collect tons of $$$$$$$$$$$$ on your stock holdings.

    There are 2 interim analysis scheduled for utility.
    definition: To see if thr new treatment is unlikely to beat the control group/arm. If yes than stop the trial

    Per the SPA this utility analysis is going to be based on months of survival nothing more nothing less.

    I hope this explanation helps

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I have to assume these looks via utility analysis is based on number of deaths

      box

      • 1 Reply to boxcarlong
      • Box, Cormack has said a couple of times (most recently at the end of the Q&A during the Q4 CC) that there will be two futility and one interim efficacy analysis. He wouldn't say whether any of those analyses have already occurred and he said there would be no announcement unless the trial is stopped.

        Summer has said that when she has time she'll explain how a futility analysis is done. I'm interested in that, as well as in getting her take on whether if SYNERGY passes both futility tests we should draw any encouragement regarding the efficacy or the final analysis. I hope she's able to find the time.

 
OGXI
3.31+0.01(+0.30%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.